97 related articles for article (PubMed ID: 16890381)
21. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
23. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.
Tao RH; Maruyama IN
J Cell Sci; 2008 Oct; 121(Pt 19):3207-17. PubMed ID: 18782861
[TBL] [Abstract][Full Text] [Related]
24. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
25. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
26. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Chakraborty AK; Liang K; DiGiovanna MP
Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family.
Leuchowius KJ; Weibrecht I; Landegren U; Gedda L; Söderberg O
Cytometry A; 2009 Oct; 75(10):833-9. PubMed ID: 19650109
[TBL] [Abstract][Full Text] [Related]
28. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
29. Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage.
Urbanelli L; Ronchini C; Fontana L; Menard S; Orlandi R; Monaci P
J Mol Biol; 2001 Nov; 313(5):965-76. PubMed ID: 11700053
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneities in EGF receptor density at the cell surface can lead to concave up scatchard plot of EGF binding.
Mayawala K; Vlachos DG; Edwards JS
FEBS Lett; 2005 Jun; 579(14):3043-7. PubMed ID: 15896781
[TBL] [Abstract][Full Text] [Related]
31. A mathematical model for the effects of HER2 over-expression on cell cycle progression in breast cancer.
Eladdadi A; Isaacson D
Bull Math Biol; 2011 Dec; 73(12):2865-87. PubMed ID: 21814880
[TBL] [Abstract][Full Text] [Related]
32. An integrated agent-mathematical model of the effect of intercellular signalling via the epidermal growth factor receptor on cell proliferation.
Walker D; Wood S; Southgate J; Holcombe M; Smallwood R
J Theor Biol; 2006 Oct; 242(3):774-89. PubMed ID: 16765384
[TBL] [Abstract][Full Text] [Related]
33. Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation.
Kumagai T; Katsumata M; Hasegawa A; Furuuchi K; Funakoshi T; Kawase I; Greene MI
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9220-5. PubMed ID: 12867596
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane.
Orr G; Hu D; Ozçelik S; Opresko LK; Wiley HS; Colson SD
Biophys J; 2005 Aug; 89(2):1362-73. PubMed ID: 15908575
[TBL] [Abstract][Full Text] [Related]
35. Expression of HER1/EGFR protein in human soft tissue sarcomas.
Yang JL; Hannan MT; Russell PJ; Crowe PJ
Eur J Surg Oncol; 2006 May; 32(4):466-8. PubMed ID: 16524687
[TBL] [Abstract][Full Text] [Related]
36. HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue.
Olsen DA; Ostergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Jakobsen A; Brandslund I
Clin Chem Lab Med; 2009; 47(8):977-84. PubMed ID: 19548848
[TBL] [Abstract][Full Text] [Related]
37. Preservation of HER2/neu gene during evolution: possible physiological role and survival advantages.
Kurbel S; Dmitrović B; Golcić G; Dovhanj J
Med Hypotheses; 2006; 66(5):1039-40. PubMed ID: 16446054
[No Abstract] [Full Text] [Related]
38. Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells.
Huang WC; Burnouf PA; Su YC; Chen BM; Chuang KH; Lee CW; Wei PK; Cheng TL; Roffler SR
ACS Nano; 2016 Jan; 10(1):648-62. PubMed ID: 26741147
[TBL] [Abstract][Full Text] [Related]
39. Fluorescent silica nanospheres for digital counting bioassay of the breast cancer marker HER2/neu [correction of HER2/nue].
Rossi LM; Shi L; Rosenzweig N; Rosenzweig Z
Biosens Bioelectron; 2006 Apr; 21(10):1900-6. PubMed ID: 16546369
[TBL] [Abstract][Full Text] [Related]
40. Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation.
Barta P; Björkelund H; Andersson K
Nucl Med Commun; 2011 Sep; 32(9):863-7. PubMed ID: 21760560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
